{"id":"pj009","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Hyperthyroidism"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"PJ009 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells and thereby enhancing T cell-mediated anti-tumor responses.","oneSentence":"PJ009 is a monoclonal antibody targeting PD-1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:21.260Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT06512584","phase":"PHASE3","title":"Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition","status":"RECRUITING","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2024-09-03","conditions":"Short Bowel Syndrome","enrollment":72},{"nctId":"NCT06523101","phase":"PHASE1","title":"A Study of PJ009 in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Chongqing Peg-Bio Biopharm Co., Ltd.","startDate":"2023-02-28","conditions":"Short Bowel Syndrome","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucagon-like Peptide-2 (GLP-2) analogue","Glucagon-Like Peptide 2 (GLP-2) analogue","GLP-2 analogue Placebo"],"phase":"phase_3","status":"active","brandName":"PJ009","genericName":"PJ009","companyName":"Chongqing Peg-Bio Biopharm Co., Ltd.","companyId":"chongqing-peg-bio-biopharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PJ009 is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}